"Ultimately, it isn't clear
that they would reduce spending for health plans, or by how much. There are
also outstanding questions about whether the threat of authorized generic entry
could reduce traditional generic entry, which further complicates this question."
— Stacie Dusetzina, Ph.D., associate professor of health policy
at Vanderbilt University School of Medicine, spoke with AIS's RADAR on Drug Benefits about
why payers and patients likely won't see much benefit from increased pushback
against authorized generic drugs.
Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment